Penggunaan Darurat, BPOM Izinkan Vaksin Zifivax Asal China
Indonesia approves COVID-19 vaccine of China´s Zhifei unit
Editor : Ismail Gani
Translator : Novita Cahyadi
Badan Pengawasan Obat dan Makanan [BPOM] telah menyetujui izin penggunaan vaksin Covid-19 Zifivax yang diproduksi oleh perusahaan asal China, Anhui Zhifei Longcom Biopharmaceutical untuk penggunaan darurat.
Penny Lukito selaku Kepala BPOM mengatakan, vaksin rekombinan protein yang diberikan tiga kali dalam waktu tiga bulan ini memiliki tingkat efikasi sekitar 81%, dengan efikasi 77,47% terhadap varian Delta, lebih rendah dibandingkan varian lainnya, pada Kamis [7/10].
Uji coba vaksin Zifivax dilakukan di China, Uzbekistan, Pakistan, Ekuador, dan Indonesia, yang melibatkan 28.000 orang, dengan kemanjuran berdasarkan tingkat keparahan.
Direktur Utama PT Jakarta Biopharmaceutical Industry [JBio] Mahendra Suhardono yang bermitra dengan Zhifei, mengatakan suntikan Zifivax bisa diproduksi di Indonesia tahun ini.
Zhifei dan unitnya, Anhui Zhifei Longcom Biopharmaceutical, tidak segera memberi komentar, seperti dikutip Reuters yang dilansir MailOnline.
INDONESIA has approved a COVID-19 vaccine produced by a unit of China´s Chongqing Zhifei Biological Products for emergency use, its food and drug agency (BPOM) said on Thursday, the fourth Chinese vaccine cleared for use in the country.
BPOM chief Penny Lukito said the protein-recombinant vaccine, given three times in a three-month span, has an efficacy rate of about 81%, with 77.47% efficacy against the Delta variant, lower than other variants, she said.
Trials of the vaccine, Zifivax, were conducted in China, Uzbekistan, Pakistan, Ecuador and Indonesia, involving 28,000 people, with the efficacy based on any degree of severity.
Indonesia has also approved use of the Sinovac, Sinopharm, and CanSino vaccines.
Once Asia´s COVID-19 epicentre, Indonesia has vaccinated a fifth of its population of about 270 million people.
It has recorded more than 4.2 million coronavirus cases and 142,000 deaths overall, but average daily infections have fallen dramatically since the peak of its crisis in July.
Mahendra Suhardono, head of Jakarta Biopharmaceutical Industry, which is partnering with Zhifei, said Zifivax shots could be produced in Indonesia this year.
Zhifei and its unit, Anhui Zhifei Longcom Biopharmaceutical, did not immediately respond to requests for comment.